Prostate cancer is the most common form of cancer among men in England, with cases surging by 25 per cent between 2019 and 2023, according to NHS data. It’s also the second-deadliest form of the ...

A new at-home saliva test for prostate cancer could outperform current testing methods, a new study suggests. Researchers have developed a simple spit test, that can be performed at home and does not ...

Former President Joe Biden received his last known blood test to check for prostate cancer in 2014, a spokesperson said Tuesday — two days after Biden revealed he has an aggressive form of prostate ...

The study's testing accurately identified prostate cancer 91% of the time and accurately ruled out men without prostate cancer 84% of the time. A urine-based biomarker panel may be a promising, ...

READ MORE: Scandal of NHS prostate cancer postcode lottery: Thousands of men at greater risk of death as 96 trusts fail to meet target to start treatment, forcing hundreds to wait months for care A ...

The NHS will not be automatically inviting all men above a certain age to check for prostate cancer, unlike the approach for some other cancers. The UK National Screening Committee has suggested that ...

Rishi Sunak has urged men to be checked for prostate cancer as part of a new screening drive. The former prime minister has given his backing to an initiative run by the charity P ...

Prostate cancer is one of the most frequently diagnosed cancers in men yet is often highly treatable when detected early. It originates in the prostate gland, located between the bladder and the penis ...

CAMBRIDGE, England--(BUSINESS WIRE)--Scientists in Cambridge have developed a new ‘super test’ for prostate cancer in an effort to revolutionise screening and diagnosis of the disease and accelerate ...

Mdxhealth Highlights Data from Oxford’s ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple ...

Australian scientists say it could also help reduce the risk of overdiagnosis by determining which cancers are low-risk and ...

A new immunotherapy drug has demonstrated early promise in a recent prostate cancer clinical trial. The drug, called VIR-5500, is a "masked T-cell engager". This type of immunotherapy ignites our own ...